-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DKVZDLTthQEAI8Cb+b0nhOltUliABbt5qeiXIRqoIhldhhY4Xjou0HY4HO2QkJmK lkyUWwg01uVgLaEAJGGexw== 0001193125-09-235866.txt : 20091116 0001193125-09-235866.hdr.sgml : 20091116 20091116165314 ACCESSION NUMBER: 0001193125-09-235866 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20091110 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20091116 DATE AS OF CHANGE: 20091116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US ONCOLOGY INC CENTRAL INDEX KEY: 0000943061 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 841213501 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26190 FILM NUMBER: 091187736 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DR STREET 2: STE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: 2818732674 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN ONCOLOGY RESOURCES INC /DE/ DATE OF NAME CHANGE: 19950327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US Oncology Holdings, Inc. CENTRAL INDEX KEY: 0001333191 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 200873619 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-126922 FILM NUMBER: 091187735 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DRIVE, SUITE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: (832) 601-8766 MAIL ADDRESS: STREET 1: 16825 NORTHCHASE DRIVE, SUITE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (date of earliest event reported) – November 10, 2009

 

 

US Oncology Holdings, Inc.

US Oncology, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   333-144492   20-0873619
Delaware   0-26190   84-1213501

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

10101 Woodloch Forest

The Woodlands, Texas 77380

(Address of principal executive offices including zip code)

(281) 863-1000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 8.01 Other Events.

On November 10, 2009, US Oncology and US Oncology Holdings, Inc. (the “Companies”), announced that Phillip H. Watts, Executive Vice President and General Counsel of each of the Companies, will be retiring from the Companies, effective November 30, 2009.

 

ITEM 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this Current Report on Form 8-K:

(c) Exhibits.

 

Exhibit 99.1   Press Release of US Oncology, Inc. dated November 10, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 10, 2009

 

US ONCOLOGY HOLDINGS, INC.
US ONCOLOGY, INC.
By:  

/S/    PHILLIP H. WATTS        

Name:   Phillip H. Watts
Title:   Vice President - General Counsel
 EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

LOGO

US Oncology Announces Retirement of General Counsel Phil Watts

The Woodlands, Texas (Nov. 10, 2009) — Today, US Oncology, Inc. announced that Phillip Watts, executive vice president and general counsel, will be departing from the Company, effective November 30, 2009.

Watts has had a long and rich history with US Oncology. Beginning in 1993, he worked with US Oncology providing legal services and consultation as an outside attorney before joining the Company in 1998 as its General Counsel.

“Phil has been involved in the US Oncology organization for 16 years,” said CEO Bruce Broussard. “In that context, he is going to take some time away from business to spend quality time with his family prior to continuing his career. While we will miss Phil’s wit, logical analysis and leadership, we wish him the best as he takes some time with his family to reflect on his next stage of life.”

During his tenure at US Oncology, Watts has demonstrated his leadership by developing a strong and experienced legal team, which will remain with the company. US Oncology will conduct a search for Watts’ replacement, which will include internal candidates.

In addition to his legal responsibilities, Watts oversaw the company’s strategic initiatives and public policy activities, which both will be supported by Grant Bogle, executive vice president, Integrated Oncology Solutions Group with US Oncology.

About US Oncology

US Oncology, Inc., headquartered in The Woodlands, Texas, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation’s foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system—from drug development to distribution and outcomes measurement—enabling the company to help increase the efficiency and safety of cancer care. According to the company’s last quarterly earnings report, US Oncology is affiliated with 1,310 physicians operating in 493 locations, including 98 radiation oncology facilities in 39 states. For more information, visit the company’s Web site, www.usoncology.com.

Media Contact:

Jennifer Horspool

(281) 863-6739

Jennifer.Horspool@usoncology.com

# # #

GRAPHIC 3 g98549ex99-1_pg001.jpg GRAPHIC begin 644 g98549ex99-1_pg001.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`/0#(`P$1``(1`0,1`?_$`*T```$%`0`#`0$````` M```````&!P@)"@4!`@0#"P$!``$$`P$!``````````````$"`P@)!`4'!@H0 M```&`@`%!`$"`P0%#0````$"`P0%!@<(`!$5%@D2$Q07&"$*,2(D06$C)5&! M,C,F<9'!T>%EE;0?Z_\`HX16DJK\H6][C43'D%!8W?12F<<@/FRM>;OFJ,BE7*G%.DUYRR2< MD#J+*J%$1;FX]Q\&>)D\E[[?R=W5QQC"MD766H^Y=?Z;= ML'W1B+C4Z`4/43%#Y4>?F\,\:L8?'7M-SK/=395AW"UCVWK=O.O0JU/M(I-2 M69Q7MDW];\WUK8_"F/,RU42I1UT@V[]U'@H"JT'.-Q49V&`=B!C"1>(F6ZZ` M\^0F*4I_X&#CS/FW%<_A/+,WBVX5-_$R&7NI07$ZV[@J-0RT(IZZ3W/QMS?` M\D<(V[F>V,HM9V.KNH-?MW1I>M'6OT/4"NM*&E#'VX^:GWD.$0X1#A$.$0X1 M#A$.$0X1#A$.$0X1#A$.$0X1#A$.$0X1#A$.$0X1#A$1&2+[6,6T6UY%NDBC M%52EP,G8IU\L8I?9CXUJ=PH5$#&("KMP8H)(I@/J56.4A>8F`..PVC:L[?MU MQMCVM&N;EEWEMVU`ZLQI7\*#6OI.BY-R':^(\?R^4;W=%G:,"P]ZZQ_I0$T' MNQ_2H]6('K,#^QN=;9LEF:]9AN3IPH_MKFFWCKN@DFR6']`*^2;&'D M!U!''_Y1^,'Y-Q]>>;:G_NMMMC[UL4[KF,*G4#4FPU6]25)]A,K?A1YN3A_* M&\=<@N]O'=XOC_'9C]-G,H$`J=`M\40]`&"GWFM,AP.'\!#].?+]?^3]/X#Q MKN1UN*'35"H(_(])M\J*T]:G^$I`\QGE+S'XJZ5CS*L=A;&N9J'DO("&.86* M>WRUTVX1DJG3IJUR$I)J(52?A%XT#0AT$4TC`J(*%,80Y"'%4KMI]QNVM).W M078;*.V>LV*MD\AU.@T:.S50*CD2G56E3MCL+V$C+''*O'499I.=AX5!Q(,U M#)%(HU2]HX>L1`/Y>:4L*,1[&--=MJMD\7[,7JBY&HVN]7U?QGA.2V2NN?7F M2[^%CB,715HG821A%XB1$=+3_`';BMLKMLICQ+%-_Q-;]5KQ5<691@,FD5@2EVKPJQ$D@#TBB)WR(^1;$GCQQI4K M'[DFPRDLL11)DF MNF!4UEE445$1'Y_SSO+J[KA9-HKS2,`Y988KJZN1,TX&Q:TR!7;A$T2';]0N MXXORK9;),05[LM*A06=E1D:Y`MI@C10I%&1CD#A$EIJOM%AK:A,W&-!"H/JTU2[C9LF"**YC/SM?<.8Q0$``.(K+HM$IWU]) MHGXF6H<(APB>.8?PYAS']0X1//"(<(GJ\3 M,'YI]SN[YUMJKCFP"XKM2>IRF8U8XI#-I"U-EB]'J2LBDJ)A1K8B99ZAZ1*= MX9(IOYD.0YU_%OQH^!:/D+>;2_Y5\=N&K?J6VP^J\J]"6.B-U"ZCK-6'S@\V M_P"[YW_R7B^57`Q7+;@5Z/>4@I8+#TM]74Z%^WU6X]0`IT)ECX2>"<+DZYGD?F., MM_:$%W%Q;5P`A[EU"+]YE;T2VW8G3ZF+C5095]MO@.0U#V>M^,4%WSF(J\[' MV>A3#@AD7O<%I_JF*7F;Q]D>&O+.9QO&-T8./DID8=QJC MNLDBY:8'U9:%"P.K*9L6TCV%:;'X(IUT4?(.K"G$MV<\!%4C.%U4#K-$)-TD MFHJ"#Q[\0Y7:8&,"+])=,!$"@/&LWR7P[)X/R_+V2ZO;CK=)MCV4Z@?E0BE? M2DW0^#?(UCR=X_P>1=P.?]E4O:U)913N/XM3ZO9JB9V?W?W_`+/-5/\`Y/// M_*2]\?`^D]IQ_P"Y+N?#?_\`ECH5S_C^,V,^?_@I.$M/^MOS/\Y&#RU8NOF: M,<[Y8SQC&OIJ]VCQH.TJ_!Q@&/)3JT7EJTS;R"CT2`*CE[-1TDS<>,;]T`?4[7O$VL6RVO-@R34<00C&AU;*V,++%1]Q;4:& M$6D%%6:@6ANQC)>7K<>!68N&\LS,ND@3W$`6`YSQ67S9'I-;7CJV,T[W.<9V MW%U)R&K:!S.]Q?$Y13+LZ3)`HB()EY)7VC[?=ZUFXO9"':V+7?/5?>D* MHSG,+Y1AW:9PYD4:R='G62Y#AR'F4Z2X@/\`=PE,P;_MH?(+9-3,*[^0=GI= MIR9AW#V-:[M?+0U5Z+LTC&LI-W9&;2*-\=%5(QEF0"8 M>9^?"%@4;2ZE)::9.UX=_5G-<6!XV MD$S$*HF10ATTU4CD!+;KV&D9N3\S>/?Q-NGD"K6%[1*:0TZRO*^QRI8KI7J1 MD;)[2,N25!?V/$6'9A@JXLD8[M!E6\6WDYB#E)3V#BFT*'H]241]LU>5G53$ M6%M: M_P"/]^#[&/$>LY2?V3^1FIZR>0FCRFWLMHMK]5%<[;%TFA&R;F%BC9V5+QQA M6IGJL] ME6@XA=1;M[><=4:6M[9VG\R2BGTRFW4!!J*8@<42IO6C;WR#^+#`N>]Z=I;1 M<_(=HQG#(]$7UMMD?GUA8KE'5>^R-I?5O++IA9J^[<4BMW"/?1<5)P:BK-6) MGB@E\(A.:G"<@VT)[5T82^?&7DKL69?'2AY#L8Z_1]MK[JMS]V;8D9YJC&]P M4K543DF5BAQF7=!1A29/8V>)7C$X$0]ERN!!3?F]PA#):=0IIZQ\Z)MW>I?+ M&.L,Y*UZL6-;G=:AFO6Q_CM MY`3H)^^5/WC)1.OO-M37-4,"V2\O)5DWN4NV7@,:0ZA47;Z9M;HI$TUV\:LJ MD+IE!(+?+=FY"1),@>K_`&@`?1?%OC_#A&WM`LME8F*;>,*@*CA>VV&"ZA0WZJ:@:TZ30^-PR,OIXWQ/A[-!JI5H)A#L$E M8NH1C@B,:U1:('?+K6ITK(2#@B?J56']!.(C_;RXP:W'XP>4^4;K?WSD.X[0 M=SR+S.Y^Y>(!))^G_P`70=!0])L[V'YL^">#;!B\23>?6C=&M4=]2<:9)K&6:6^<-FEHL"=9:1*]2D/;6 ME*]*$C)24>R7)Z4J[(P`F#98JOZB58P<>Q>$?$G/?%^[Y2[IF8.1QS*3ZK:& MZS"\-$N(&4`4&C'UTTT$QV^3?GSQ9YRV+#N[+MFYXW,,)Z)>O"P$-AOUVV[+ MK,U#0IIIK[Z)+Q2[71^O>?F%=NTTZCL>9#0-77#ES)I,H6!F72Z:[:2DQD9& M/BVD%F6937BET+?L% MTW#<-X.PXZN MY,V5V)18-95E@'2;%]SMC=V58[5"`E<^WH9'W/860.5X%8KDJX0+ZP'UH%$0 M,7]!2B,OM1X$_%WO0\>Y<=XN=8XNV0FZ5G/E?7>SGHPVI6<:)/V5H?UY-O+8 M\GUI))P1RHZ4B16=B<3G4,8WJXFDG[SIH*D2GSP&:L7_`$$\Q_D:TR=VQSLB+]N8W(%"\T@LIQPNG=W?\`>;A-DIIK6]=L]V)\H1)E M`X6RE-/%5#`5--K%T:=?.%%#")0*0B2`B(B(``!PEB?SNO#=@2S%\77FMVDD M(]RRJ3!&F+OVL;9]H],:MD5:/]T.>/I)C.+2#9 MZ=+_`&(V0GVD:V7YCZ5"+>V;F!N0Q.0X'_]OMJEK7G> M/FY'&UQITQ+2"]5FU:Y98FQ5S.=WGHJHK(J$$Q%$SE, M(<3.&^CD_C**=R\=US`W[A+Q8ZHXX!ZTPAJZ72G&N(JX_DG4PX@8=Y=96SSJ MLC(.^:C^QSTP_!Z_<#_B+"*0B!2%3*5*V93;].ZLEA^\,?RT./CFFJRX=,[7 M$V_/,E6W<<W/835%W:D#I@D="R.-<)9:;1.D4`!,RLN:?:-.FO\`UB^_;,3ETM/E:\H5FR7<\F*GSR6539"1).-UR MJB*B?PWB`(E(/+VR)E*`````!*+I0H.VG6(>9D)1K^Z[SW#DFEJY1[A6LB5? M-$PF\+%Q\7AI[H_'O;E/3L@J8C)C&UQW',I$'#@021=-D3B/,`YS(M@=I_9) M/X%TKVCQYX3=M?&;3,$Y0R5DO-.8;@IKQDY&`:T_$61\3W2VXVD:YE:>LMQE M8=]C2-3@:T\'J$\863I^ M/M3@VN\WC2PVQH@KTMID6?=RMP2L4"1VF5T:.IV1)1->..1'(33T?X"(C`ER\5)!76;V0(4.0B`&,`&#U"`";D8P&,' M/E^@"8`'E_=Q,LRCSR6>/#8W:_+=+R+C&\TM_7JY5DX1"BWY^\C(VMR";U=X MZDHALC!3,?*!."9,SLSCDH8R":8E%(A>,I_`_F?A?CO9,S8^0XV6E_(R/N-D M8Z*S7+?;149F8$=C5[>W2C$]9@K\H_CKY(\N\MV_DO$,S#;`QL06O\7*N,BV MK@8LSH`C*1<':&KKIT(I*Z)_PV;X7J;7FKQ:L4R$H9JTCTI-Q='KD/AQC-)C M%L&S-I6&*#".9MDRI(H))D303+_(7^P?:L7Y,>(-FPSB;)BYZVB[/V?9%`[: MLS,;C.[,>K,=?:8U;K\+//W(]Q_W#?\`+VBYDE0O=_D5^E0`B*OVE5>T"BA0 MHH-=8K5O`YGL`YM\P8T'D"!!!>-GB&,ND/0)P,H(CZ0`"\S=BORX M\>E`3A;H'IT"6Z5]@>_^,ZYO@%Y4#$+G;014:_=N"H)ZT[#2@U/[HKZ?X%WBH=IVG,OY#'ZEO.MI5770,H<# M&Q5H$>RMR^7K^H]C"V%`'0DD]U-/67CY@T8Q?LQI<73#99P_RA5GE#J]6F+@ M4Q8>TA9:BV9=!R)`/"%=='M4/*L$WC9005()BBFL"J1U2'P9WO.Q]TWG+W3% ML+C6,G(N7!:4U"!V)"UH*T%!6DV>\2V;+X[Q?;]@S\I\W,PL.U9>^P"M=:V@ M4N5&@K3I*N-(/'%Y3_&]`2FOVO>W^K.9]5@G)67H,9LGB3*)Y1D3*,W3Y<[I5@M(-V1WBBJJ!6@+*%'J]9],SJPZ'NI+"KWX_P!#*NJV MRN`\IY@[$X/I+)2)PP?8]]9ZCE[%]52 M$20M!G;UC^LVB&RQ6:NCZ48U=>)@Y)!F4K9198J:9RHCA:>:5-M8;WVAG+N=L;>(3=J"DB MY.5,Q43WR)XX:1&^.RQ^.35E:K8/Q;9<7V'$BLW.P,K=91C#6V.?(6.XK)LY MZM+6+($M+/!?.7;UP*3A+'*WC_P!+,R:V\?%-VL\?^#D MM2L9YJP]DK!]4L]MDL1Y"R=3K@EE>B5:Y3CVRNJI8ZE69IE3[^O!3NQ-7VJ2:,<*:!#(J)$Z^7/&S M,;G;4:V;(;L3./)BJ:C)S$SB'`&,6=@D*A/Y-GI*`DU\B9,MEN2C9&890;BJ MQYXVOMXY)J"Z'N.G3D@BB9$BSEOPK97RGY3:9Y2#[+8_A[G0I:FO(7$)$O"X`G90])*F*\9I\" M[WY(\@6I,]2ZO>M@:(YINQV%[Y'3"6,[_-N):'GRY.J-DKWSI_']Q/,0A%'Z M(L)5C)BNLH)6ZZAU3)9D?YWQGX,P)5?)INQMSEEN^S3N'A_*U6RWERN5MZTJ M^!\0VFE)4YMC[#-47?OYZ<L6LO_=LTU4]W[)HX\$N3-M;AI_?L;[NS2G;>C-S)RF0X/`F.)UN1FDC&Q&1'U1:Y$RZ6.<$,<7*UDCW%-DW@_P`I M@?+K@/")@D`1`1Y_I_8`\@_U@'\>*2H8@GJ)!`/6'H*']G%73II%%'0 M">?2']X<(H!H.D!*`_VC_P`_"05!T](%*!>?+G_K'GRX:^L!0I)'K/;A*H<( MAPB'"(<(APB'"(<(APB'"(<(APB'"(<(APB,=LM@.G[1X%RMK]?%Y%G5LK4V M4J^+I MK&CIU+7>?O3.);PIL[2M_NL?4W[INV*V[XDL+,*"K.EE'(D^2M`(68C45S"D M26(F(*%1*N_(]X:/KIF#)(M5F07S*%E]E:S3C9FY7=.FD0V*W0CXU)5115*,9-R',)BB/")) M3A$.$0X1#A$.$0X1(2;0[6.\#W?'%?B&=5DHA)(N0L\+3K]RUDZA@T;-"8]4 MLM8103=[ZO0[E6V1*-D5?'36^98 MJ-XR<--5=U1=+#U$N4Y?!I;QC-&E';JG62LF1?*/(]%LNS821F9W!FIA!$6F M1-Z,+8TLKROSR%O<,HJ\LL>35O81L(E3XZQO$Z()V[63F;'#O;8I&K9$CTG; M:":RK]L%*=5Y\G0'*B3U%T,8FV2^8,@H@J`)(G- M=^0'#S>,0FV]0S#*Q#-I4EKU(15&1=)XHD;OD:7Q-`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`1:5(4B'%94:23$K-TN:[-!*U M5:.%7P."@0412/ZT18U_8JCRV.\H9'G8^SX]CL+.K6TRE"WR/CHV>IRU0K;& MYR1WY8F7G(5VUYAQ82+9'1" MZ%MD+BQ+"R< M(%H?9`5K=\2B9=NFM:8I1FU@I5\K+H/2BV4`I5E$41=K;BTANVMDFC0LNS%6 MJ2EGCBY"C*:Q)0+7/4:S1],N4/7[%(V)FWC#05F>*MSO9WI$2J1@]51>*HM% ME"HCU89R]4UZP"8P(V\:-^2:WQPR^;)X!D@)_[O][J(UH!E>G>CJW^ M7?$'A$E]D7\4.P\=]2^X.7Q\T?4?:GI[Z[V_)[%OR>UO>_IAR#]^]O\`;/RO MZ#V/<^7_`$GO\(GW47Z.^PL>]Z?DR.:>[Z;S'-7Q0LXV?NK87ML9\($1I05[ MY?'G-GQE^0SZL-[$O.0LRVWB MOZU?[RBE'3>MV=M-Y*&8;QGQGD0I%P`"XF.H1PLVP(ED6TG8WVW7NV1V6#/O MU3.=9_%<*8-M^C`GP]T+Q]DB%.Z::U_("OBV_P"*`??-&(`0^:'")!B;_!?N MRU?+_*4:I\/*WO@]Z:$(%H_$XWVB,B-G`=@S7$<(_P"Z"W`#$)?U_`YJ>]PB M2@SU])_;=L[<_)G\B.HF^:.NH5HX_L6G_20X@^-]P?;7P97H78@2 M(]M=0[9ZKU3K0]`Z%\_J/]'[W")6]DK\9^IQ_P!J_FX.00@Y_P"W^[PQ\%U- M4_MBF@EW-U41C25(;KTH6?U-ZH[I?,'/]-ZAX1'7S!^+';V+/B?=P3GQ]JNB M_7GUL-V^O_MDGY`!-?:7*$Z&.1O@])&'_P"+`5]CI',WR.$1_=C_`,:^C8>^ MR>_^E_7=G[`[9ZA[_:'5,.=1ZQU/_-.H?(Z![7R/ZCT_(]S^?U<(GU9-_'#Z M[VH[^[L^NOOBB?D9\KV0A.J]`P3\@9/WP%#Z;[/Z)W."G^#TKJ7O#[/N<(C8 MP/X$?D?0OI/MGO/J-(]X==>S?J$+3T7-O8'V.%%_R4;AV]WA\3UB#KX7/W/\ M/V.$1'Y"_#+Z@Q[W!]K=N]JYG^LOA?"[H"7_`"=Q/U'IHRP=%&Z_?';O0.H_ MY7\3W?F_TGO\(G0J_P",'8]]Z\.(C[09)Y4W])3I8_&%7DB6$Z>_7?T='_6/?W;W?V9.I_9_3^^ ?.^OMZ[_9/6ND?Y+R[_ZE\;X/]!\3VOC?X'M\(G__V3\_ ` end -----END PRIVACY-ENHANCED MESSAGE-----